Work with leaders in nephrology clinical research
Streamline your clinical development with operational expertise
Leverage proprietary data to inform study design choices
Barbara S. Gillespie, MD, MMS, FASN
Vice President and Therapeutic Head of Nephrology, Labcorp Drug Development
Adjunct Professor, University of North Carolina School of Medicine, Division of Nephrology and Hypertension
Dr. Gillespie, board-certified in nephrology, joined Labcorp in 2017 after over a decade of leadership experience at Quintiles, where she held a variety of positions. These duties included reporting directly to the Chief Medical and Scientific Officer and serving as Global Therapeutic Lead for Nephrology and North American Head of the U.S. Internal Medicine team.
Dr. Gillespie serves on the board of directors of the Kidney Health Initiative (a public-private partnership between the FDA and the American Society of Nephrology) as well as on the steering committee for the National Kidney Foundation (NKF) Chronic Kidney Disease Registry. She is also on the board of directors for Nephronet and the Cardio Renal Society of America, has served on several global work groups and advisory boards for academic and trial-related stakeholders (including NKF, NephCure, Kidney Disease Improving Global Outcomes, ISN, Patient-Centered Outcomes Research Institute/University of North Carolina and PREPARE-NS) and has presented in many global forums and renal conferences.
She is also a past associate medical director at a small local dialysis unit and a fellow of the American Society of Nephrology. Dr. Gillespie received board certification in internal medicine in 2004 and in nephrology in 2006 and 2015. She completed her internal medicine residency at University of North Carolina and her nephrology fellowship at Duke.
Jennifer Ennis, MD
Medical Director, Clinical and Digital Solutions Labcorp Diagnostics
Dr. Ennis, board-certified in internal medicine and nephrology, joined Labcorp Diagnostics as a medical director in 2009. In this role, she led the development of Labcorp’s suite of laboratory-based clinical decision support offerings, including chronic kidney disease, cardiovascular disease and diabetes. In 2020, she became Medical Director of Clinical and Digital Solutions, where she provides clinical direction and oversight for Labcorp's portfolio of customer-facing technology solutions and leads a team of clinicians in creating content for the portfolio. She provides subject-matter expertise for nephrology initiatives throughout the organization and serves as a Labcorp representative on the National Kidney Foundation Laboratory Engagement Committee.
Dr. Ennis is also a clinical associate professor of medicine in the section of nephrology at the University of Illinois at Chicago where she sees patients weekly, lectures and supervises medical trainees. In addition to these responsibilities, she performs clinical research in chronic kidney disease and has authored several abstracts and peer-reviewed publications.
Dr. Ennis earned her MD from the University of Pittsburgh School of Medicine and completed internal medicine residency and nephrology fellowship training at the University of Chicago Medical Center. She is a fellow of the American College of Physicians.
Katherine T. Landschulz, PhD
Senior Director and Therapeutic Area Lead Cardiovascular, Metabolic, Renal and Neurodegenerative Diseases, Labcorp Biomarker Solution Center
Dr. Landschulz joined Labcorp Drug Development in 2010, after more than a decade as a scientist in discovery through translational medicine roles at Pfizer, Abbott and Eli Lilly. At Labcorp, Dr. Landschulz helped establish the exploratory biomarker laboratory, Translational Biomarker Solutions, and served as associate director of this team prior to joining the newly established Biomarker Solution Center in 2018.
As Renal Disease Therapeutic Area Lead for the Labcorp Biomarker Solution Center, Dr. Landschulz is responsible for the delivery of biomarker strategies for sponsor programs in renal disease indications (e.g., acute kidney injury, chronic/diabetic kidney disease). Dr. Landschulz serves as a consultant to sponsors and teams, advising on matters related to biomarker selection and strategy development, laboratory placement of testing, feasibility designs and overall guidance around translational and exploratory biomarker data in drug development. Dr. Landschulz serves further as a liaison, directing questions and connecting sponsor and Labcorp biomarker scientists. Finally, Dr. Landschulz participates in enterprise-wide assessments and the licensing and implementation of new laboratory biomarker and tests transitioning from clinical trial to clinical care utilization.
Dr. Landschulz received her BSc in genetics at the University of California, Davis and her PhD in genetics/biology from Johns Hopkins University. She completed postdoctoral studies at both Johns Hopkins and University of Texas, Southwestern Medical School prior to joining the biopharmaceutical industry in 1997.
From supporting first in human studies in our Phase I units to designing, planning, managing and operationalizing global Phase II to IV studies, we are your trusted source for conducting renal studies. Our medical and operational experience encompasses a broad range of nephrology indications including but not limited to the following areas:
- Acute kidney injury
- Diabetic kidney disease
- Chronic kidney disease and associated complications (e.g., hyperkalemia and hyperphosphatemia)
- Glomerular disease including focal segmental glomerulosclerosis, IgA nephropathy and lupus nephritis
- End-stage kidney disease: dialysis (and associated complications such as cardiovascular outcomes) and kidney transplant
- Rare renal diseases
- Renal devices
- Renal impairment
- Renal cell carcinoma
Develop new perspectives through proprietary data
Prioritizing a patient’s journey and associated data is critical in delivering successful trials. At Labcorp, we can create and apply a strategy applicable to your study’s specific indication and patient population. Starting with vast patient diagnostic data from Labcorp’s database of longitudinal patient data and site-specific recruitment metrics from our Central Laboratory and clinical investigator database, we can:
- Design the most efficient trial by focusing on the highest enrolling countries and sites and eliminating nonperformers
- Identify patients meeting your inclusion criteria who are near clinical trial sites and connect them to your trial
- Fully inform your protocol design to maximize recruitment and save time and money
Comprehensive, multifunctional nephrology experience and expertise to deliver better outcomes
Whether your study is looking for a rare population, expecting aggressive enrollment timelines or operating in a highly competitive environment, Labcorp has the expertise, data and experience to support trial design, proactively mitigate risk and deliver results.